ANTI-CLDN4/ANTI-CD137 BISPECIFIC ANTIBODY

Abstract: an object of the present invention is to provide an anti-cldn4/anti-cd137 bispecific antibody usable in treatment of cancer. an anti-cldn4/anti-cd137 bispecific antibody produced using an anti-cldn4 antibody binding to cldn4 and an anti-cd137 antibody binding to cd137 had agonistic activity for cd137, promoted production of interferon � by a t cell, and exhibited cytotoxic activity against a cancer cell expressing cldn4 on a cell surface thereof. besides, it was shown that the anti-cldn4/anti-cd137 bispecific antibody can be safely administered to monkeys. therefore, the anti-cldn4/anti-cd137 bispecific antibody is usable in treatment of human cancer.

Inventor(s): Yoshiyuki TENDA, Masatoshi YURI, Shigenori YAGI, Yoshiki SATAKE, Kazunori HIRAYAMA, Hiroki SHIRAI, Hiroki SASAKI, Fumiko CHIWAKI, Masayuki KOMATSU

CPC Classification: C07K16/2878 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250154272